Ovarian cysts: GP approach to risk stratification and surveillance

What ovarian cysts are — and why finding one is usually not alarming

An ovarian cyst is a fluid-filled or partly-solid sac arising from the ovary. Finding one on pelvic ultrasound is one of the most common gynaecological incidental findings in general practice. The critical first question — asked before ordering additional tests or making a referral — is whether the cyst represents a normal variant of the menstrual cycle or something that needs further investigation.

In premenopausal women, the answer is usually reassuring. Functional cysts — the follicular cyst (a dominant Graafian follicle that failed to rupture at ovulation) and the corpus luteum cyst (the post-ovulatory structure, sometimes filling with blood) — represent the majority of ovarian cysts in cycling women. They arise as a normal consequence of the monthly hormonal cycle and resolve spontaneously in most cases within two to three cycles. The risk of malignancy in an asymptomatic simple cyst in a premenopausal woman is approximately 1 in 1,000 (RCOG GTG 62).

The clinical picture changes significantly after menopause. The ovaries are no longer cycling, so any cyst requires a clinical explanation. Even so, around 50% of simple unilocular postmenopausal cysts under 5 cm resolve without intervention — and a unilateral simple cyst of 1 cm or less needs no follow-up at all (RCOG GTG 34).

Australian ovarian cancer statistics provide the essential context: approximately 1 in 87 Australian women will develop ovarian cancer in their lifetime, with around 1,815 new cases diagnosed each year and a five-year survival rate of approximately 49% — largely because most cases are diagnosed at an advanced stage (Ovarian Cancer Australia). This is the backdrop against which appropriate vigilance — rather than unnecessary intervention — matters most in general practice.

A. Core clinical — the AU general-practice framework

When to suspect a cyst

Many ovarian cysts are found incidentally on pelvic ultrasound requested for an unrelated reason. Symptoms that should prompt consideration of an ovarian cyst or adnexal mass include:

• Pelvic or lower abdominal pain — intermittent, cyclical (suggesting endometrioma), or acute (rupture or torsion)
• Abdominal bloating, eating less, abdominal pain, toilet urgency — the BEAT symptom set used by Ovarian Cancer Australia; any combination of these symptoms in a postmenopausal woman warrants prompt assessment
• Palpable pelvic or abdominal mass on examination
• Menstrual irregularity — particularly in the context of oestrogen-secreting sex-cord tumours or PCOS
• Pressure symptoms — urinary frequency, incomplete voiding, constipation from a large mass
• Virilisation or premature puberty — rare presentation of androgen-secreting tumours

History to take

A focused history covers:

• Pain character and timing — sudden severe onset (torsion, rupture) versus intermittent dull ache versus cyclical premenstrual pain (endometrioma); radiation to the groin or inner thigh
• LMP and menstrual cycle — regularity, perimenopausal symptoms, date of menopause
• Pregnancy status — serum β-hCG is mandatory in any premenopausal woman with adnexal mass and pain before any other investigation is ordered; ectopic pregnancy must be excluded first
• Contraception — combined oral contraceptive use; intrauterine device (raises PID and tubo-ovarian abscess risk)
• Bleeding — postcoital, intermenstrual, postmenopausal (see postmenopausal bleeding assessment)
• Constitutional symptoms — unintentional weight loss, anorexia, early satiety, abdominal distension (suggesting advanced malignancy)
• Past history — endometriosis, pelvic inflammatory disease, prior pelvic surgery, previous ovarian cyst, fertility treatment
• Family history — ovarian, breast, colorectal, or endometrial cancer in first-degree relatives; known BRCA1/2 or Lynch syndrome mutation substantially raises lifetime malignancy risk (BRCA1 approximately 40%, BRCA2 approximately 15%; eviQ Cancer Genetics)
• Medications — tamoxifen; fertility medications including follicle-stimulating hormone (which can cause large bilateral theca lutein cysts)

Examination

• Vital signs — haemodynamic instability or fever points to emergency presentations (rupture with haemoperitoneum, tubo-ovarian abscess)
• Abdominal palpation — distension, palpable mass, guarding, rebound tenderness, ascites (assessed for shifting dullness)
• Bimanual pelvic examination — adnexal mass size and mobility (fixity suggests malignancy or endometriosis); cervical motion tenderness (PID, torsion, ectopic)
• Rectal examination — posterior cul-de-sac nodularity suggests endometriosis or peritoneal disease
• Supraclavicular lymphadenopathy — in women where advanced malignancy is a concern

Investigations

β-hCG — always first in premenopausal women with pain. A serum or urine β-hCG must be obtained before any imaging or referral decision for any premenopausal woman with adnexal mass and pain. A missed ectopic pregnancy is among the highest-litigation events in gynaecological general practice.

Pelvic ultrasound — transvaginal (TVUS) is preferred in sexually active patients; it provides superior resolution of adnexal structures compared with transabdominal imaging alone. The request wording should specify pelvic ultrasound, transvaginal preferred to ensure adequate characterisation (MBS item 55065). From 1 November 2025, MBS item 55080 funds a longer complex gynaecological ultrasound for conditions including severe endometriosis and adenomyosis.

CA-125 — selective use only. In postmenopausal women with an ovarian cyst, CA-125 is recommended as part of the Risk of Malignancy Index calculation. In premenopausal women, CA-125 is unreliable as a primary marker: endometriosis, uterine fibroids, pelvic inflammatory disease, pregnancy, menstruation, and peritoneal inflammation all raise CA-125 without cancer, producing a high false-positive rate (RACGP AFP 2015). Reserve CA-125 in premenopause for women with suspicious ultrasound features, a strong family history of ovarian or breast cancer, or ascites.

Tumour markers in women under 40. When a complex or solid mass is identified in a woman under 40, request AFP, LDH, β-hCG, and inhibin alongside standard investigations. These markers detect germ-cell malignancies (dysgerminoma, yolk-sac tumour) and sex-cord stromal tumours (granulosa cell tumour), which occur preferentially in younger women.

MRI pelvis — the next-step imaging modality when ultrasound findings are indeterminate or a cyst exceeds 7 cm (where ultrasound characterisation is limited by the field of view). MRI is the preferred modality in pregnancy — no ionising radiation, superior soft-tissue detail without contrast.

CT is reserved for staging once malignancy has been confirmed and is not a first-line tool for characterising an ovarian cyst.

Safety-netting in plain language

Before a patient leaves the consultation: “Most ovarian cysts are harmless fluid sacs that come and go with your cycle. We’re monitoring this one with a repeat scan. Go to emergency immediately if you get sudden, very severe lower abdominal pain — especially with vomiting — call an ambulance. Also go straight in for dizziness, fainting, fever with belly pain, or any rapid deterioration. Otherwise come back if the pain worsens or anything doesn’t feel right.”

B. Risk stratification — from ultrasound to decision

The Risk of Malignancy Index

The RMI (Risk of Malignancy Index) is the most widely used stratification tool in Australian general practice because it can be calculated at the consulting desk from the ultrasound report and a CA-125 result (Jacobs 1990, BJOG):

RMI = U × M × CA-125

• U (ultrasound score): count features — multilocular cyst, solid areas, bilateral lesions, ascites, intra-abdominal metastases. 0 features = score 0; 1 feature = score 1; 2 or more features = score 3.
• M (menopausal status): premenopausal = 1; postmenopausal = 3.
• CA-125: serum value in U/mL.

RMI score	Risk	Management
<25	Low	Conservative — monitor per guideline surveillance schedule
25–200	Intermediate	Consider MRI; general gynaecology review
≥200	High	Urgent gynaecological oncology MDT referral

RMI ≥200 is the threshold for referring to a gynaecological oncologist rather than a general gynaecologist (RACGP AFP 2015).

IOTA Simple Rules

Where the ultrasound report includes IOTA characterisation, the Simple Rules classify masses by five benign features against five malignant features:

• B-features (benign): unilocular; solid components <7 mm; acoustic shadowing; smooth multilocular tumour <10 cm; no Doppler blood flow
• M-features (malignant): irregular solid tumour; ascites; four or more papillary structures; irregular multilocular-solid tumour ≥10 cm; very strong Doppler flow

Where only B-features are present: likely benign. Where only M-features: likely malignant. If both or neither apply: inconclusive — refer for specialist assessment. Simple Rules classify approximately 76% of adnexal masses with sensitivity ~93% and specificity ~90%.

Premenopausal management pathway

Per RCOG GTG 62:

Ultrasound finding	Management
Simple <5 cm	No action — physiological; reassure; no repeat scan required
Simple 5–7 cm	Repeat ultrasound in 8–12 weeks
Simple >7 cm	Gynaecology referral ± MRI
Any complex feature	Gynaecology referral; RMI; AFP/LDH/β-hCG/inhibin if under 40
Dermoid (mature teratoma) suspected	Elective laparoscopic cystectomy — ongoing torsion risk warrants intervention regardless of size
Endometrioma	Small and asymptomatic — surveillance; >4 cm or significant dysmenorrhoea — gynaecology (see endometriosis management)

Postmenopausal management pathway

Per RCOG GTG 34:

Ultrasound finding	Management
Simple unilocular ≤1 cm	No follow-up required
Simple 1–7 cm + CA-125 <35 U/mL	Ultrasound and CA-125 every 4 months × 1 year; discharge if stable
Simple >7 cm	MRI or gynaecology review — ultrasound characterisation is unreliable at this size
Complex, solid, bilateral, raised CA-125, or ascites	Urgent gynaecological oncology referral

C. Key clinical evidence

The oral contraceptive does not shrink existing cysts

A persistent clinical myth is that prescribing the combined oral contraceptive (COCP) will shrink an existing functional ovarian cyst. A Cochrane review (Grimes 2014, CD006134) examined eight randomised controlled trials involving 686 women and found no acceleration of cyst resolution with oral contraceptives compared with watchful waiting.

What the COCP does do — and this is clinically relevant — is suppress ovulation and reduce the incidence of new functional cysts. It is therefore appropriate in women with recurrent symptomatic functional cysts as a preventive strategy, but not as treatment of an existing one.

Surveillance is safe for most simple postmenopausal cysts

Observational data and guideline evidence support conservative surveillance for simple postmenopausal cysts under 7 cm with a normal CA-125. Approximately 50% of these cysts resolve spontaneously over a surveillance period, and the malignancy rate in a simple unilocular cyst with normal CA-125 remains less than 1% (RCOG GTG 34). Elective surgery in postmenopausal women carries meaningful anaesthetic and surgical morbidity; the surveillance pathway avoids unnecessary intervention in the majority.

Dermoid cysts — the exception to watchful waiting

Mature cystic teratomas (dermoids) are the most common benign ovarian tumour in women aged 20–40 and carry an estimated torsion risk of approximately 15%. Even small, asymptomatic dermoids are often referred for elective laparoscopic cystectomy, because the torsion risk persists until the cyst is removed. Their characteristic ultrasound appearance — echogenic fat, acoustic shadowing, sometimes calcification from calcified tissues — usually allows confident diagnosis without additional imaging.

D. Australian operations

MBS items relevant to ovarian cyst management

• Item 55065 — pelvic ultrasound (any approach: transabdominal, transvaginal, or combined). Schedule fee $112.85, 75% benefit $84.65 (effective 1 July 2025). Cannot be claimed for obstetric purposes — separate obstetric items apply.
• Item 55080 — complex gynaecological ultrasound (from 1 November 2025), for conditions including severe endometriosis, adenomyosis, and chronic pelvic inflammatory disease. Higher schedule fee than 55065.
• Items 36 / 44 — standard GP consultations of ≥20 or ≥40 minutes respectively; appropriate for initial cyst assessment and results discussion.
• Item 715 — Aboriginal and Torres Strait Islander Health Assessment; a structured entry point for women with limited prior gynaecological screening.
• Items 2715 / 2717 — Mental Health Treatment Plan (preparation and review); appropriate when a cyst diagnosis causes significant anxiety, or when chronic endometrioma-related pain warrants psychologist input.
• Items 965 / 967 — GP Chronic Disease Management Plan; applicable when ongoing endometriosis or chronic pelvic pain creates care coordination needs across multiple providers.

PBS-listed medicines

• Combined oral contraceptive (e.g. Microgynon 30, Levlen ED) — PBS general schedule; for contraception and prevention of recurrent functional cysts.
• Mefenamic acid, naproxen — PBS general schedule for cyclic pelvic pain and dysmenorrhoea.
• GnRH agonists (goserelin, leuprorelin) — PBS Authority for endometriosis-related management; gynaecologist-initiated.

State-based gynaecological oncology referral centres

For any cyst meeting urgent referral criteria (RMI ≥200, complex postmenopausal cyst, suspected malignancy), refer to:

State	Centre
VIC	Royal Women’s Hospital; Peter MacCallum Cancer Centre
NSW	Royal Hospital for Women (Randwick); Westmead Hospital
QLD	Royal Brisbane and Women’s Hospital; Mater Mothers’
WA	King Edward Memorial Hospital; Fiona Stanley Hospital
SA	Royal Adelaide Hospital; Flinders Medical Centre
TAS	Royal Hobart Hospital
ACT	Centenary Hospital for Women and Children
NT	Royal Darwin Hospital (with interstate referral for gynae-oncology)

For public-sector triage, the Queensland Health Clinical Prioritisation Criteria for ovarian cyst and pelvic mass is a practical template applicable across Australian states. Suspected malignancy is category 1 (within 30 days); symptomatic benign cyst is category 2 (within 90 days).

Medico-legal documentation points

Three documentation steps carry disproportionate medicolegal significance:

1. Record the β-hCG result in any premenopausal woman with adnexal mass and pain — a missed ectopic is among the highest-litigation events in general practice.
2. Document reasoning for non-referral when a complex or postmenopausal cyst meets guideline thresholds — the clinical rationale should be explicit in the notes.
3. Request pelvic ultrasound as “transvaginal preferred” — transabdominal imaging alone is inadequate for adnexal characterisation in most cases.

E. Special populations

Adolescents and young women. Functional cysts and mature cystic teratomas dominate this age group. Germ-cell malignancies (dysgerminoma, yolk-sac tumour, immature teratoma) are rare but occur predominantly in adolescents and young adults — request AFP, LDH, and β-hCG for any solid or complex adnexal mass. Laparoscopic ovary-sparing cystectomy is the standard surgical approach; fertility preservation should be a central goal.

Pregnancy. Around 1–6% of pregnancies have an adnexal mass identified at the booking or dating scan. Most are corpus luteum cysts and resolve by 16 weeks; reassure and arrange a repeat scan. Persistent masses beyond 16 weeks warrant MRI (no ionising radiation; no contrast required) for further characterisation. Surgical intervention during pregnancy is reserved for torsion, rupture, haemodynamic compromise, or strongly suspected malignancy; if elective surgery is unavoidable, the second trimester (14–22 weeks) is the preferred window.

BRCA1/2 and Lynch syndrome. Women with BRCA1 or BRCA2 pathogenic variants and any new adnexal mass warrant expedited referral to both gynaecological oncology and familial cancer services (eviQ Cancer Genetics). Risk-reducing bilateral salpingo-oophorectomy is recommended at approximately 35–40 years (BRCA1) or 40–45 years (BRCA2) — but this is a specialist-led shared decision and should not be proposed in a general practice consultation without specialist input.

Aboriginal and Torres Strait Islander women. Geographic and cultural barriers to pelvic imaging access and specialist gynaecology are well documented and contribute to later-stage ovarian cancer diagnosis and worse outcomes in this community. Community-controlled health services often provide more culturally acceptable referral pathways. The ATSI Health Assessment (MBS item 715) provides a structured opportunity to raise ovarian cancer symptom awareness and facilitate referral where appropriate.

When to escalate

Emergency — call 000 or go directly to ED:

• Sudden severe lower abdominal pain, particularly with vomiting — suspected ovarian torsion
• Haemodynamic instability with pelvic free fluid — ruptured haemorrhagic cyst
• Fever with adnexal mass and cervical motion tenderness — tubo-ovarian abscess
• Syncope or collapse with known adnexal mass

Urgent gynaecological oncology referral (within 2 weeks):

• Postmenopausal complex, solid, or bilateral cyst
• RMI ≥200
• Ascites with adnexal mass
• Raised CA-125 plus suspicious ultrasound features
• Known BRCA1/2 or Lynch syndrome with any new adnexal mass

General gynaecology referral (within 4–8 weeks):

• Premenopausal simple cyst persisting at repeat 8–12-week scan
• Endometrioma >4 cm or causing significant pain or infertility
• Dermoid (mature teratoma) of any size — elective cystectomy
• Simple premenopausal cyst >7 cm — MRI and gynaecology review

What this article is and is not

This article draws on current Australian gynaecological guidelines — RANZCOG, RACGP Australian Family Physician, the RCOG Green-top Guidelines used as international reference, eviQ, and Ovarian Cancer Australia — to provide general health information for patients and general practitioners. It is not personal medical advice and does not establish a patient–doctor relationship. Individual management decisions depend on the complete clinical context and are made with your treating clinicians.

For trusted consumer-level information: Jean Hailes for Women’s Health, Healthdirect — Ovarian cysts, and Ovarian Cancer Australia. For cancer-specific information or telephone support: Cancer Council Helpline 13 11 20.

---

Sources cited

1. RACGP Australian Family Physician 2015 — Investigation and management of an ovarian mass
2. RANZCOG — Ovarian cysts patient information
3. eviQ — Ovarian cancer treatment protocols
4. eviQ Cancer Genetics — BRCA1 risk management
5. Ovarian Cancer Australia — About ovarian cancer
6. Ovarian Cancer Australia — BEAT symptom set
7. Jean Hailes for Women’s Health — Ovarian cysts
8. Healthdirect — Ovarian cysts
9. Queensland Health Clinical Prioritisation Criteria — Ovarian cyst and pelvic mass
10. MBS Online — item 55065 pelvic ultrasound
11. MBS Online — item 715 ATSI Health Assessment
12. RCOG Green-top Guideline 62 — Premenopausal adnexal masses
13. RCOG Green-top Guideline 34 — Ovarian cysts in postmenopausal women
14. Grimes DA et al. Cochrane CD006134 (2014) — Oral contraceptives for functional ovarian cysts
15. Jacobs I et al. BJOG 1990 — Risk of Malignancy Index incorporating CA-125, ultrasound and menopausal status